Cochrane Review Group
Epilepsy
77 systematic reviews in Epilepsy ask 970 questions. 19.6% have no studies to answer them, 13.9% rest on very low certainty evidence and 32.3% reach moderate or high certainty.
Reviews
77
Questions
970
current versions
No studies
19.6%
Moderate or high
32.3%
No studies 190 · 19.6%Ungraded 42 · 4.3%Very low 135 · 13.9%Low 289 · 29.8%Moderate 242 · 24.9%High 72 · 7.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Immunomodulatory interventions vs placebo Seizure freedom · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Allergic reactions · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Cognitive effects · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Quality of life · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 1 year of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane | RR 0.76 [0.58, 1.01] | 1 study · 149 participants | Very low |
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 2 years of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane | RR 0.87 [0.58, 1.29] | 1 study · 149 participants | Very low |
Rapid vs slow withdrawal of antiepileptic drugs Seizure freedom after 5 years of AED withdrawal · people with epilepsy Rapid versus slow withdrawal of antiepileptic drugs (2022) · Cochrane | RR 1.4 [0.54, 3.65] | 1 study · 149 participants | Very low |
Intervention NR Primary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary seizure prophylaxis after stroke · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Pregabalin vs placebo Adverse effect: headache · drug‐resistant focal epilepsy Pregabalin add‐on for drug‐resistant focal epilepsy (2022) · Cochrane | RR 0.65 [0.45, 0.94] | 6 studies · 1850 participants | Very low |
Pregabalin vs active comparators 50% or greater reduction in seizure frequency ‐ best‐case analysis · drug‐resistant focal epilepsy Pregabalin add‐on for drug‐resistant focal epilepsy (2022) · Cochrane | RR 1.6 [1.17, 2.19] | 3 studies · 1286 participants | Very low |
Reviews 77
Lamotrigine add‐on therapy for drug‐resistant focal epilepsy
CochraneSoF table
7 questions
Immunomodulatory interventions for focal epilepsy
CochraneSoF table
7 questions
Perampanel add‐on for drug‐resistant focal epilepsy
CochraneSoF table
7 questions
Prognosis of adults and children following a first unprovoked seizure
CochraneSoF table
9 questions
Vagus nerve stimulation for focal seizures
CochraneSoF table
7 questions
Rapid versus slow withdrawal of antiepileptic drugs
CochraneSoF table
3 questions
Antiepileptic drugs for the primary and secondary prevention of seizures after stroke
CochraneSoF table
6 questions
Pregabalin add‐on for drug‐resistant focal epilepsy
CochraneSoF table
26 questions
Care delivery and self‐management strategies for children with epilepsy
CochraneSoF table
8 questions
Felbamate add‐on therapy for drug‐resistant focal epilepsy
CochraneSoF table
5 questions
Stiripentol add‐on therapy for drug‐resistant focal epilepsy
CochraneSoF table
7 questions
Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data
CochraneSoF table
15 questions
Brivaracetam add‐on therapy for drug‐resistant epilepsy
CochraneSoF table
5 questions
Clonazepam monotherapy for treating people with newly diagnosed epilepsy
CochraneSoF table
10 questions
Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy
CochraneSoF table
12 questions
Gabapentin add‐on treatment for drug‐resistant focal epilepsy
CochraneSoF table
8 questions
Prophylactic drug management for febrile seizures in children
CochraneSoF table
105 questions
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents
CochraneSoF table
12 questions
Anti‐seizure medications for Lennox‐Gastaut syndrome
CochraneSoF table
33 questions
Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure
CochraneSoF table
8 questions
Lacosamide add‐on therapy for focal epilepsy
CochraneSoF table
7 questions
Eslicarbazepine acetate add‐on therapy for drug‐resistant focal epilepsy
CochraneSoF table
6 questions
Antiepileptic drugs for seizure control in people with neurocysticercosis
CochraneSoF table
2 questions
Topiramate for juvenile myoclonic epilepsy
CochraneSoF table
7 questions
Sulthiame monotherapy for epilepsy
CochraneSoF table
23 questions